Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dacomitinib in advanced NSCLC (ARCHER 1042)
NCT01465802Phase 2Completed
- Sponsor
- Pfizer
- Start
- Dec 2011
- Primary completion
- May 2015
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 2
01
Overview
A Phase 2 trial of dacomitinib in non-small cell lung cancer (NSCLC), sponsored by Pfizer. Started Dec 2011; status: completed.
02
Drugs
dacomitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01465802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01465802.